AbCellera director buys 10,000 shares at $11.03
AbCellera Biologics Inc. (ABCL) director John S. Montalbano reported purchasing 10,000 Common Shares on 2026-08-18 at $11.03 per share in an open-market or private transaction.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
AbCellera Biologics Inc. (ABCL) director John S. Montalbano reported purchasing 10,000 Common Shares on 2026-08-18 at $11.03 per share in an open-market or private transaction. After this purchase, he directly holds 251,000 Common Shares, and there is an additional 5,000 Common Shares reported as indirectly owned by his spouse. The filing indicates these transactions were not reported under a Rule 10b5-1 trading plan.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Shares | 10,000 | $11.03 | $110K |
| holding | Common Shares | -- | -- | -- |
Key Figures
Key Terms
indirect ownership financial
Rule 10b5-1 trading plan regulatory
open-market or private transaction financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did ABCL director John S. Montalbano report on this Form 4?
Are any of John S. Montalbano’s AbCellera (ABCL) holdings reported as indirectly owned?
AI-generated analysis. How Rhea-AI works. Not financial advice.